Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Ahh the little games being played -- I'v been sitting at .0352 with a partial buy after slapping the ask earlier today. So they just give someone .035 and ignore my order. MM Bastards.
Nupapa
I would really like to know if this was a $PGTI window.
https://www.yahoo.com/gma/florida-school-shooting-suspect-fired-hurricane-proof-window-150903566--abc-news-topstories.html
Nupapa
I always say "I have an eye problem - Can't see coming in."
Purchase and Sale Agreement $TVOG -- more news coming soon, IMO
The Company has finalized its phase 1 infrastructure and shipping acquisition agreement in conjunction with the Preferred Stock placement with Network 1 Securities, Inc. (“Network 1”). The Company has executed a conditional Purchase and Sale Agreement (“Agreement”) through a portfolio company of a multi-generational family office based in Dubai, United Arab Emirates. This agreement remains subject to closing conditions which Turner and counterparties are working to meet by early March 2018. This family office has investments and operating businesses that include dry shipping, crude shipping, natural resource development, construction, civil engineering, and banking. Their investment into Turner will focus on bitumen (also known as asphalt), and the supply chain and transportation of bitumen.
https://ih.advfn.com/p.php?pid=nmona&article=76816654
Ah crap - I monkey thumbed that key - You're correct.
NASDAQ requires $1 - let that sink in folks
And to that point — note that they say “in the near future” when talking about a higher exchange than OTCQB. $TVOG
“Finishing the audit and Form 10 will immediately allow the Company to submit application to uplist to the OTCQB, and will make for a much smoother transition for when the company uplists to a higher exchange in the near future. The Form 10 Registration Statement is a registration statement used to register a class of securities pursuant to Section 12(g) of the Securities Exchange Act of 1934 (“Exchange Act”).”
What's great about that statement - it comes from the banker, not Steve. More confirmation IMO that $TVOG is doing things the right way.
Nupapa
$VUME +22% on News
$VUME NEWS OUT
https://www.otcmarkets.com/stock/VUME/news/story?e&id=1013989
VuMee Inc. Enters Definitive Agreement to Purchase Operator of Medical Marijuana Cultivation Centers
Montana Apothecary LLC and DC's Finest, LLC cultivate medical marijuana for the Washington, D.C., area. Company plans to expand into other markets following closing of acquisition
Washington, D.C. /TheNewswire /February 26, 2018 - VuMee Inc. (OTCMKTS: VUME) ("VuMee") today announced that on February 23, 2018, it entered into a Share Exchange Agreement by which it plans to issue its common stock in exchange for 100% of the equity interests in each of Montana Apothecary, LLC (d.b.a. Alternative Solutions Cultivation Center) and DC's Finest LLC (the "Target Companies"). Montana Apothecary LLC develops and operates medical marijuana cultivation centers which sell to fully-licensed medical marijuana distributors in the Washington, D.C., metro area. The company currently operates an 18,000 square foot cultivation center, and is developing a second cultivation center, both within Washington, D.C., city limits. DC's Finest, LLC owns licenses and permits to cultivate medical marijuana but currently does not engage in cultivation operations.
Vumee President and CEO Sean Jahanian said, "Upon the closing of the share exchange, VuMee plans to issue an amount of common stock which would result in the members of the Target Companies owning a majority of the voting stock of VuMee. The Share Exchange Agreement also obligates VuMee to provide operating capital for the Target Companies, and to renegotiate the Target Companies' existing debt obligations." The Share Exchange Agreement contains standard representations and warranties, covenants and closing conditions and may be terminated in the event that either party cannot meet its closing obligations within 90 days. The parties intend to close the share exchange in the first quarter of 2018.
In addition to serving the Washington, D.C., market, the Target Companies plan to expand into other domestic and international markets.
$RIGL | FDA has set April 17, 2018 as date to complete its review of RIGL drug Fostamatinib under the Prescription Drug User Fee Act (PDUFA).
Fostamatinib, if approved by the FDA, could become an important alternative treatment option for patients with chronic ITP. Additionally, RIGL has shown in preliminary results that 47% of the patients treated with fostamatinib in an autoimmune hemolytic anemia study had a clinical response as measured by a defined increase in hemoglobin. There are currently no approved therapies for this indication.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=138586302
Nupapa
Rigel Pharma Awaits FDA Approval for Tavalisse, Builds Commercial Org for Drug Launch
Published: Jan 15, 2018 By Alex Keown
The first half of 2018 will be pivotal for Bay Area-based Rigel Pharmaceuticals, Inc. as the company awaits regulatory approval for its rare blood disorder drug and builds out the internal infrastructure to commercialize the product.
The U.S. Food and Drug Administration is set to rule on Tavalisse (fostamatinib disodium), an oral spleen tyrosine kinase (SYK) inhibitor, for adult patients with chronic or persistent immune thrombocytopenia (ITP) on April 17. ITP is a rare autoimmune disorder that affects about 65,000 people in the United States. The disease attacks and destroys the body's own blood platelets, which play an active role in blood clotting and healing. Rigel filed its New Drug Application in the spring of 2017 based on Phase III data that showed patients treated with the drug achieved a prospectively defined stable platelet response.
“This is a very exciting time for us,” Rigel Chief Executive Officer Raul Rodriguez told BioSpace in an exclusive interview.
Rigel has been working with fostamatinib for more than a decade and despite some setbacks, including a 2016 failure in adult chronic/persistent immune thrombocytopenia and rheumatoid arthritis, Rodriguez said being this close to possible approval is “monumental.”
“We’ve had to recover some and show some grit, but when you have failures and stumbles, it behooves you to go forward,” Rodriguez said.
Rodriguez said that if Tavalisse is approved by the FDA, the company plans to have the product available for patients by the summer. If all goes well with the FDA, Rodriguez said Rigel will treat ASCO (American Society of Clinical Oncology) in the summer as a “coming out party” for Tavalisse.
To facilitate a successful launch Rodriguez said the company has been putting together a commercial team of about 50 people, the majority of whom are sales reps. The company is building a distribution system of specialty pharmacies to get the drug in the hands of patients, Rodriguez said.
“It would be great to have patients begin to benefit with all the work we’ve done over the past 10 years. It will be incredibly gratifying,” he said.
In addition to chronic or persistent ITP, Rigel is also studying the effects of Tavalisse on patients with autoimmune hemolytic anemia (AIHA), a disorder similar to ITP, but where antibodies attack red blood cells rather than platelets. There is no FDA approved treatment for the approximately 40,000 patients in the U.S. with this disease, Rodriguez said. In a small trial of 17 patients with AIHA, about 47 percent had positive results with Tavalisse. Rodriguez called it a potential game-changer for improving the quality of life for those patients.
Rigel is also anticipating Phase II results from a Tavalisse for patients with IgA nephropathy, an autoimmune disease that can prevent the kidney from filtering waste from the body’s blood. Data is expected in late March or early April.
“There’s nothing approved for this and we hope to show a benefit with fostamatinib at a higher dose,” Rodriguez said.
Not only did Rodriguez use last week’s J.P. Morgan conference setting to showcase Rigel’s pipeline, but he is also actively seeking a candidate to fill the company’s empty chief financial officer position. In December, Rigel’s then-CFO Ryan Maynard announced he was leaving the company at the end of the year. While Nelson Cabatuan, Rigel's vice president of finance is temporarily filling the spot, Rodriguez said he is interviewing candidates. Rodriguez said he is looking to hire a CFO with commercial experience prior to commercial launch of Tavalisse as it will be critical for the company to have someone in this position when the company gets a drug on the market.
“You know, the thing about J.P. Morgan is every single CFO candidate with commercial experience is sitting within four blocks of where I’m sitting,” Rodriguez said. He added that over the course of the week-long conference he had multiple interviews with candidates and hopes to fill the position within the next three months.
Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), a pharmaceutical company developing therapies for ophthalmic diseases, today reported financial results and operating highlights for its fiscal first quarter ended December 31, 2017.
“We recently announced top-line results from the MAKO study evaluating the efficacy and safety of topically administered squalamine in combination with monthly Lucentis® injections for the treatment of wet-AMD, which did not meet its primary efficacy endpoint,” said Dr. Jason Slakter, chief executive officer of Ohr Pharmaceutical. “Based on these results, we have discontinued development of squalamine, taken measures to preserve cash and are evaluating strategic alternatives to maximize shareholder value.”
Corporate Highlights for the Fiscal First Quarter Ended December 31, 2017
Reported topline data from the MAKO study which did not meet its primary efficacy endpoint. There were no differences in the safety profile between the two treatment groups. The MAKO study evaluated the efficacy and safety of topically administered squalamine in combination with monthly Lucentis® injections for the treatment of wet age-related macular degeneration (“wet-AMD”). Based on the results, the Company has discontinued further development of squalamine and is evaluating strategic alternatives.
The Board of Directors has engaged Roth Capital Markets, LLC, to advise the Board of Directors and management, and to assist in pursuing a range of strategic alternatives.?
Financial Results for the Quarter ended December 31, 2017
For the quarter ended December 31, 2017, the Company reported a net loss of approximately $4.2 million, or ($0.07) per share, compared to a net loss of approximately $7.0 million, or ($0.21) per share in the same period of 2016.
For the quarter ended December 31, 2017, total operating expenses were approximately $4.2 million, consisting of $1.5 million in general and administrative expenses, $2.4 million of research and development expenses, and $0.3 million in depreciation and amortization. This compares to total operating expenses of $7.0 million in the same period of 2016, comprised of approximately $1.7 million in general and administrative expenses, $4.9 million in research and development expenses, and $0.3 million in depreciation and amortization.
At December 31, 2017, the Company had cash and cash equivalents of approximately $8.7 million. This compares to cash and equivalents of approximately $12.8 million at September 30, 2017.
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995:
This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made only as the date thereof, and we undertake no obligation to update or revise the forward-looking statement whether as a result of new information, future events or otherwise. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including our ability to raise sufficient funds to perform and conclude clinical trials, the financial resources available to us, the ability to negotiate and conclude a strategic partnership, the future success of our scientific studies, our ability to successfully develop products, rapid technological change in our markets, changes in demand for our future products, legislative, regulatory and competitive developments, and general economic conditions. Shareholders and prospective investors are cautioned that no assurance of the efficacy of pharmaceutical products can be claimed or assured until final testing; and no assurance or warranty can be made that the FDA will approve final testing or marketing of any pharmaceutical product. Our most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q discuss some of the important risk factors that may affect our business, results of operations and financial condition.
Contact:
Ohr Pharmaceutical Inc.
Investor Relations
888-388-2327
ir@ohrpharmaceutical.com
Fingers crossed they come back with something positive for shareholders very soon. Doubled my position today to try to overcome the New Year’s disaster.
GLTA
NP
PrimeStar Bitumen -- Yes ticker change is coming. Not sure on ticker.
Read this from CEO LinkedIn blog:
https://www.linkedin.com/pulse/family-office-perspective-convergence-bullish-rallies-steve-helm?trk=mp-reader-card
Nupapa
381,400 Buy at .04 -- I'd say someone expecting big things is accumulating $TVOG.
Nupapa
$TVOG train about to leave the station IMO.
.0399 is up
NP
Nice volume and buys this morning. $TVOG
Nupapa
$VUME NEWS OUT
VuMee Inc. Announces Change in Management
https://www.otcmarkets.com/stock/VUME/news
(via TheNewswire)
Accepts resignation of Joseph Arcaro from position of President and member of Board of Directors
Appoints Sean Jahanian as new President and board member
Scottsdale, AZ /TheNewswire /January 29, 2018 - VuMee Inc. (OTCMKTS: VUME) today announced that on January 22, 2018, its Board of Directors accepted the resignation of Joseph Arcaro from his position as the company's President and member of the Board of Directors. Contemporaneously with Mr. Arcaro's resignation, the Board appointed Sean Jahanian as the company's new President and member of the Board of Directors. This announcement follows the company's announcement on January 23, 2018, that it has entered into a letter of intent to acquire all of the issued and outstanding equity interests of Montana Apothecary LLC d.b.a. Alternative Solutions Cultivation Center, a developer and operator of medical marijuana cultivation centers which sell to fully-licensed medical marijuana distributors in the Washington, D.C., metro area.
"I am honored to serve as president of VuMee Inc.," said Mr. Jahanian about the appointment. "I look forward to focusing the company's efforts at acquiring cash-flowing assets and growing long-term shareholder value."
Sean Jahanian has a twenty-five-year track record of providing strategic business development and technical operations leadership in uniquely challenging situations, including international commodities development (oil, gas and minerals), transportation and logistics, sales and marketing, strategic communications and global security consulting. He previously held senior positions with a Washington, D.C.-based strategic consulting firm and a Dubai-based power plant contractor. Mr. Jahanian brings the high-level strategic planning and execution experience that the company needs to identify and acquire quality cash-flowing businesses over the long-term, and in the short-term to navigate the complex regulatory environment which governs the fast-growing medical and consumer marijuana sector.
No problem. Easy to forget all the details during the waiting period when things are slow. Always like to remind myself why I bought in and what’s coming.
GLTA
NP
Thanks for sharing.
$TVOG is holding steady
NP
Thx although I failed to include the blockchain focus you mentioned:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=137494186
$TVOG will explode soon enough IMO. Still accumulating so I'm in no rush.
Nupapa
$TVOG has a lot of catalysts in the works.
-- Name Change & Ticker Symbol change
-- New Management/BOD expected
-- M&A announcements expected based on 12/11 PR
-- Plans to Uplist
http://www.nasdaq.com/press-release/turner-announces-completion-of-bitumen-shipping-acquisition--placement-agreement-20171211-00460
Part of Steve's blog from December. Expect news soon on several items:
https://www.linkedin.com/pulse/family-office-perspective-convergence-bullish-rallies-steve-helm/
I am happy to announce that yesterday, December 11 2017, we did in fact close on this historic event in company history. Infrastructure Closing Phase 1 of our initial infrastructure acquisition is now complete with 2 bitumen shipping vessels and a large financial commitment to fund asset acquisition.
That financial commitment was the result of a very positive response to our recently announced $25 Million preferred stock placement with our investment bank Network 1. In fact, so positive that there are now plans for an infrastructure investment expansion on top of this initial shipping acquisition. In June, we announced updated company guidance for our first acquisition of (5) bitumen shipping vessels with an estimated run rate of over $39,000,000 in annual revenue and $6,000,000 in EBITDA. We are already entering the shipping markets at historic lows and have developed a plan that allows us to purchase these ships for pennies on the dollar. This opens the door for an aggressive growth strategy to expand from the initial 5 bitumen tankers to up to 30 tanker ships in the next 12-18 months.
Furthermore, now that the initial deal has been finalized, PSB, working in conjunction with Network 1 and an expert team of advisors, will begin targeting the purchasing/leasing of import/export facilities, asphalt refineries, distribution facilities, and related businesses. This will give the company inroads into practically the entire supply side chain for bitumen products. We can control everything from the cost of making the bitumen, how it is stored, whom to sell it to, and how, when, and where to deliver it. And as a result, we look for revenue and profits to rise in turn as we grow as a company and the infrastructure expansion takes hold.
TVOG has a lot of catalysts in the works.
-- Name Change & Ticker Symbol change
-- New Management/BOD expected
-- M&A announcements expected based on 12/11 PR
-- Plans to Uplist
http://www.nasdaq.com/press-release/turner-announces-completion-of-bitumen-shipping-acquisition--placement-agreement-20171211-00460
Part of Steve's blog from December. Expect news soon on several items:
https://www.linkedin.com/pulse/family-office-perspective-convergence-bullish-rallies-steve-helm/
I am happy to announce that yesterday, December 11 2017, we did in fact close on this historic event in company history. Infrastructure Closing Phase 1 of our initial infrastructure acquisition is now complete with 2 bitumen shipping vessels and a large financial commitment to fund asset acquisition.
That financial commitment was the result of a very positive response to our recently announced $25 Million preferred stock placement with our investment bank Network 1. In fact, so positive that there are now plans for an infrastructure investment expansion on top of this initial shipping acquisition. In June, we announced updated company guidance for our first acquisition of (5) bitumen shipping vessels with an estimated run rate of over $39,000,000 in annual revenue and $6,000,000 in EBITDA. We are already entering the shipping markets at historic lows and have developed a plan that allows us to purchase these ships for pennies on the dollar. This opens the door for an aggressive growth strategy to expand from the initial 5 bitumen tankers to up to 30 tanker ships in the next 12-18 months.
Furthermore, now that the initial deal has been finalized, PSB, working in conjunction with Network 1 and an expert team of advisors, will begin targeting the purchasing/leasing of import/export facilities, asphalt refineries, distribution facilities, and related businesses. This will give the company inroads into practically the entire supply side chain for bitumen products. We can control everything from the cost of making the bitumen, how it is stored, whom to sell it to, and how, when, and where to deliver it. And as a result, we look for revenue and profits to rise in turn as we grow as a company and the infrastructure expansion takes hold.
$VUME's LOI partner - Montana Apothecary operates as Alternative Solutions -- for those doing DD
ASA Activist Newsletter - APRIL 2012
http://www.safeaccessnow.org/asa_activist_newsletter_april_2012
DISTRICT OF COLUMBIA The Washington D.C. Department of Health has selected six cultivation centers to provide medical cannabis to the five district distribution centers scheduled to be named this summer.
All will be located in the Northeast neighborhood of D.C., and each may grow up to 95 cannabis plants at any one time. Operators of the centers must apply for additional business licenses and building permits before beginning any cultivation, but those are typically issued within two weeks.
The cultivation location operators were selected by a six-member panel in consultation with Advisory Neighborhood Commission members. The selected operators are Abatin Wellness Center, District Growers, Holistic Remedies, Montana Apothecary dba Alternative Solutions, Phyto Management, and Venture Forth dba Center City.
The selection process was established by the D.C. Council two years ago with input from ASA, after Congress in 2009 lifted a decade-old ban on implementing the medical cannabis initiative district voters approved overwhelmingly in 1998. All laws in D.C. are subject to congressional approval.
Also from the Department of Health:
https://doh.dc.gov/release/department-health-notifies-applicants-eligible-register-medical-marijuana-cultivation
Montana Apothecary dba Alternative Solutions
2170 24th Place, NE
Washington, DC 20018
Facebook page: Montana Apothecary dba Alternative Solutions
https://www.facebook.com/AlternativesolutionsDC/
$VUME Great Call on deal.
I'd soil my drawers.
NEWS OUT: The Go Eco Group (LIBE) Announces Joint Venture with Bravatek Solutions, Inc. (BVTK)
CHESTER, N.Y., Jan. 03, 2018 (GLOBE NEWSWIRE) -- The Go Eco Group Inc. (OTC PINK:LIBE) is pleased to announce today that it has finalized a joint venture with Bravatek Solutions, Inc. to develop proprietary secure communications software for LIBE’s flagship product, the Guard Lite.
Bravatek Solutions, Inc. (BVTK) is a high technology security solutions portfolio provider that assists corporate entities, governments and individuals protect their organizations against both physical and cyber-attacks through its offering of the most technically-advanced, cost-effective and reliable software, tools and systems. The introduction of such high-end software will allow the Guard Lite a secure internet access point and multiple Guard Lights to communicate with each other.
“We’re very excited to be able to offer new and advanced features with the next generation of the Guard Lite” stated Brian Conway, CEO of LIBE. “We envision the Guard Lite to be the first 100% off the grid, solar and wind powered LED lighting and Wi-Fi security product that can also allow secure internet access within an unspecified radius. Through this partnership, we will have the level of security necessary to market to Government and municipalities in the upcoming months.”
Bravatek’s software will allow the Guard Lite to securely communicate with other Guard Lites and their owners. In addition, the NVR (video) will be hosted on a proprietary block chain that allows for the transfer of encrypted video. Mr. Conway continues, “This joint venture opens the door for our company to offer a more commercially advanced technology and solutions for the future”.
Dr. Thomas A. Cellucci, Chairman and CEO of Bravatek commented: “We’re pleased to be working with the LIBE team. Our software development prowess and sales distribution strength will allow a much needed capability to both the public and private sectors.”
About The Go Eco Group Inc.
The Go Eco Group Inc. is a diversified energy services holding company delivering conventional as well as non-conventional energy solutions throughout North America. For its customers, Liberated is an energy products and services company reducing the everyday cost of energy to its clients. For its shareholders, Liberated operates and acquires a diverse array of energy products and service companies with proven revenues and operations. Its mission is to be the best small cap energy services company of its kind in North America.
About Bravatek Solutions, Inc.
Bravatek Solutions, Inc. is a high technology security solutions portfolio provider that assists corporate entities, governments and individuals protect their organizations against both physical and cyber-attacks through its offering of the most technically-advanced, cost-effective and reliable software, tools and systems.
For more information, visit www.bravatek.com
Safe Harbor for Forward-Looking Statements: This press release may contain forward-looking information. There are many factors that could cause the Company's expectations and beliefs about its operations, its services and service offerings, its results to fail to materialize. All forward-looking statements in this press release are based on information available to us as of the date hereof, and we assume no obligation to update these forward-looking statements.
Contact:
Brian Conway
CEO
The Go Eco Group
Phone: (845) 610-3817
http://theguardlite.com
Closed just shy of the 50 MA. Should cross it tomorrow. Looking forward to a nice run here.
Nupapa
$MBRX chart heading in the right direction.
Thanks for posting. Good information.
NP
Love it if they stuck in early positive data report on Phase 3. Even a hint that the data will be positive would send this well over $2. IMO
Nupapa
As of December 8, 2017: OS 226,023,535
https://ih.advfn.com/p.php?pid=nmona&article=76266966
Not invested in RGSE -- Just stopping in to say congrats to all of you who had this one. Nice work!
I took that to mean $28 million - not the purchase price of the equipment. I also like the removal of future capital requirements and equipment maintenance costs. Put the money to better use.
Price is holding nicely today $14.95. Like to see it cross $15, but a bit of consolidation before that won't be a bad thing.
IMO
NP
Good day. Liked seeing PR today
Big buys today in the $8.70 range. Something tells me Kahn is doing more buying. Starting to wonder if they might turn activist and push for some reform.
NP
Yeah - saw all of that. The Institutions are holding the float captive for now, but that won't last.
What I liked about the Cardinal announcement was this statement:
“Cardinal has been a loyal, long-term partner for us with a consistent track record of reliably delivering high-quality products. Better leveraging their industry-leading capabilities is a sound business decision as we prepare to meet the increasing demand for impact-resistant products expected in 2018 and beyond. This new agreement allows us to heighten our focus in our core areas of window and door manufacturing, where we excel, and enables us to pay down debt by the amount of the purchase price, less taxes, and removes some of our future capital requirements and equipment maintenance costs. In addition, based upon pricing agreed upon in this supply arrangement, we expect there will be no unfavorable impact to our EBITDA margins.”
Clear sign they expect big things. A divy would be a great way to draw more interest.
All IMO
NP